Cost-Effectiveness of Shortening Treatment Duration Based on Interim PET Outcome in Patients With Diffuse Large B-cell Lymphoma
Guideline recommendations for diffuse large-B-cell lymphoma (DLBCL) treatment are shifting from long to short treatment duration, although it is still unclear whether shortening treatment duration does not cause any harm. As interim PET (I-PET) has high negative predictive value for progression, we...
Saved in:
Published in | Clinical lymphoma, myeloma and leukemia Vol. 22; no. 6; pp. 382 - 392 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Elsevier Inc
01.06.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Guideline recommendations for diffuse large-B-cell lymphoma (DLBCL) treatment are shifting from long to short treatment duration, although it is still unclear whether shortening treatment duration does not cause any harm. As interim PET (I-PET) has high negative predictive value for progression, we evaluated the cost-effectiveness of shortening treatment duration dependent on I-PET result.
We developed a Markov cohort model using the PET Re-Analysis (PETRA) database to evaluate a long treatment duration (LTD) strategy, ie 8x R-CHOP or 6x R-CHOP plus 2 R, and a short treatment duration (STD) strategy, ie 6x R-CHOP. Strategies were evaluated separately in I-PET2 positive and I-PET2 negative patients. Outcomes included total costs and quality-adjusted life-years (QALYs) per patient (pp) from a societal perspective. Net monetary benefit (NMB) per strategy was calculated using a willingness-to-pay threshold of €50,000/QALY. Robustness of model predictions was assessed in sensitivity analyses.
In I-PET2 positive patients, shortening treatment duration led to 50.4 additional deaths per 1000 patients. The STD strategy was less effective (-0.161 [95%CI: -0.343;0.028] QALYs pp) and less costly (-€2768 [95%CI: -€8420;€1105] pp). Shortening treatment duration was not cost-effective (incremental NMB -€5281). In I-PET2 negative patients, shortening treatment duration led to 5.0 additional deaths per 1000 patients and a minor difference in effectiveness (-0.007 [95%CI: -0.136;0.140] QALY pp). The STD strategy was less costly (-€5807 [95%CI: -€10,724;-€2685] pp) and led to an incremental NMB of €5449, indicating that it is cost-effective to shorten treatment duration. Robustness of these findings was underpinned by deterministic and probabilistic sensitivity analyses.
Treatment duration should not be shortened in I-PET2 positive patients whereas it is cost-effective to shorten treatment duration in I-PET2 negative patients.
Guideline recommendations for diffuse large-B-cell lymphoma treatment are shifting from long to short treatment duration. Using a Markov model, we evaluated the cost-effectiveness of this shortening in treatment duration, separately in I-PET positive and I-PET negative patients. We showed that this shift is justified for I-PET negative patients, but not for I-PET positive patients as shortening treatment duration in these patients has harmful consequences. |
---|---|
AbstractList | BACKGROUNDGuideline recommendations for diffuse large-B-cell lymphoma (DLBCL) treatment are shifting from long to short treatment duration, although it is still unclear whether shortening treatment duration does not cause any harm. As interim PET (I-PET) has high negative predictive value for progression, we evaluated the cost-effectiveness of shortening treatment duration dependent on I-PET result.MATERIALS AND METHODSWe developed a Markov cohort model using the PET Re-Analysis (PETRA) database to evaluate a long treatment duration (LTD) strategy, ie 8x R-CHOP or 6x R-CHOP plus 2 R, and a short treatment duration (STD) strategy, ie 6x R-CHOP. Strategies were evaluated separately in I-PET2 positive and I-PET2 negative patients. Outcomes included total costs and quality-adjusted life-years (QALYs) per patient (pp) from a societal perspective. Net monetary benefit (NMB) per strategy was calculated using a willingness-to-pay threshold of €50,000/QALY. Robustness of model predictions was assessed in sensitivity analyses.RESULTSIn I-PET2 positive patients, shortening treatment duration led to 50.4 additional deaths per 1000 patients. The STD strategy was less effective (-0.161 [95%CI: -0.343;0.028] QALYs pp) and less costly (-€2768 [95%CI: -€8420;€1105] pp). Shortening treatment duration was not cost-effective (incremental NMB -€5281). In I-PET2 negative patients, shortening treatment duration led to 5.0 additional deaths per 1000 patients and a minor difference in effectiveness (-0.007 [95%CI: -0.136;0.140] QALY pp). The STD strategy was less costly (-€5807 [95%CI: -€10,724;-€2685] pp) and led to an incremental NMB of €5449, indicating that it is cost-effective to shorten treatment duration. Robustness of these findings was underpinned by deterministic and probabilistic sensitivity analyses.CONCLUSIONTreatment duration should not be shortened in I-PET2 positive patients whereas it is cost-effective to shorten treatment duration in I-PET2 negative patients. Guideline recommendations for diffuse large-B-cell lymphoma (DLBCL) treatment are shifting from long to short treatment duration, although it is still unclear whether shortening treatment duration does not cause any harm. As interim PET (I-PET) has high negative predictive value for progression, we evaluated the cost-effectiveness of shortening treatment duration dependent on I-PET result. We developed a Markov cohort model using the PET Re-Analysis (PETRA) database to evaluate a long treatment duration (LTD) strategy, ie 8x R-CHOP or 6x R-CHOP plus 2 R, and a short treatment duration (STD) strategy, ie 6x R-CHOP. Strategies were evaluated separately in I-PET2 positive and I-PET2 negative patients. Outcomes included total costs and quality-adjusted life-years (QALYs) per patient (pp) from a societal perspective. Net monetary benefit (NMB) per strategy was calculated using a willingness-to-pay threshold of €50,000/QALY. Robustness of model predictions was assessed in sensitivity analyses. In I-PET2 positive patients, shortening treatment duration led to 50.4 additional deaths per 1000 patients. The STD strategy was less effective (-0.161 [95%CI: -0.343;0.028] QALYs pp) and less costly (-€2768 [95%CI: -€8420;€1105] pp). Shortening treatment duration was not cost-effective (incremental NMB -€5281). In I-PET2 negative patients, shortening treatment duration led to 5.0 additional deaths per 1000 patients and a minor difference in effectiveness (-0.007 [95%CI: -0.136;0.140] QALY pp). The STD strategy was less costly (-€5807 [95%CI: -€10,724;-€2685] pp) and led to an incremental NMB of €5449, indicating that it is cost-effective to shorten treatment duration. Robustness of these findings was underpinned by deterministic and probabilistic sensitivity analyses. Treatment duration should not be shortened in I-PET2 positive patients whereas it is cost-effective to shorten treatment duration in I-PET2 negative patients. Guideline recommendations for diffuse large-B-cell lymphoma (DLBCL) treatment are shifting from long to short treatment duration, although it is still unclear whether shortening treatment duration does not cause any harm. As interim PET (I-PET) has high negative predictive value for progression, we evaluated the cost-effectiveness of shortening treatment duration dependent on I-PET result. We developed a Markov cohort model using the PET Re-Analysis (PETRA) database to evaluate a long treatment duration (LTD) strategy, ie 8x R-CHOP or 6x R-CHOP plus 2 R, and a short treatment duration (STD) strategy, ie 6x R-CHOP. Strategies were evaluated separately in I-PET2 positive and I-PET2 negative patients. Outcomes included total costs and quality-adjusted life-years (QALYs) per patient (pp) from a societal perspective. Net monetary benefit (NMB) per strategy was calculated using a willingness-to-pay threshold of €50,000/QALY. Robustness of model predictions was assessed in sensitivity analyses. In I-PET2 positive patients, shortening treatment duration led to 50.4 additional deaths per 1000 patients. The STD strategy was less effective (-0.161 [95%CI: -0.343;0.028] QALYs pp) and less costly (-€2768 [95%CI: -€8420;€1105] pp). Shortening treatment duration was not cost-effective (incremental NMB -€5281). In I-PET2 negative patients, shortening treatment duration led to 5.0 additional deaths per 1000 patients and a minor difference in effectiveness (-0.007 [95%CI: -0.136;0.140] QALY pp). The STD strategy was less costly (-€5807 [95%CI: -€10,724;-€2685] pp) and led to an incremental NMB of €5449, indicating that it is cost-effective to shorten treatment duration. Robustness of these findings was underpinned by deterministic and probabilistic sensitivity analyses. Treatment duration should not be shortened in I-PET2 positive patients whereas it is cost-effective to shorten treatment duration in I-PET2 negative patients. Guideline recommendations for diffuse large-B-cell lymphoma treatment are shifting from long to short treatment duration. Using a Markov model, we evaluated the cost-effectiveness of this shortening in treatment duration, separately in I-PET positive and I-PET negative patients. We showed that this shift is justified for I-PET negative patients, but not for I-PET positive patients as shortening treatment duration in these patients has harmful consequences. |
Author | Carr, R Eertink, JJ Ceriani, L Coupé, VMH de Vet, HCW Zijlstra, JM Greuter, MJE Barrington, SF Hüttmann, A Mikhaeel, NG Hoekstra, OS Burggraaff, CN Jongeneel, G Dührsen, U Györke, T Zucca, E Schmitz, C Lugtenburg, PJ |
Author_xml | – sequence: 1 givenname: MJE orcidid: 0000-0002-6151-3382 surname: Greuter fullname: Greuter, MJE email: mj.greuter@amsterdamumc.nl organization: Department of Epidemiology and Data Science, Amsterdam UMC, VU University, Amsterdam, The Netherlands – sequence: 2 givenname: JJ surname: Eertink fullname: Eertink, JJ organization: Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands – sequence: 3 givenname: G surname: Jongeneel fullname: Jongeneel, G organization: Department of Epidemiology and Data Science, Amsterdam UMC, VU University, Amsterdam, The Netherlands – sequence: 4 givenname: U surname: Dührsen fullname: Dührsen, U organization: Department of Hematology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany – sequence: 5 givenname: A surname: Hüttmann fullname: Hüttmann, A organization: Department of Hematology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany – sequence: 6 givenname: C surname: Schmitz fullname: Schmitz, C organization: Department of Hematology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany – sequence: 7 givenname: PJ surname: Lugtenburg fullname: Lugtenburg, PJ organization: Erasmus MC Cancer Institute, University Medical Center Rotterdam, department of Hematology, The Netherlands – sequence: 8 givenname: SF surname: Barrington fullname: Barrington, SF organization: King's College London and Guy's and St Thomas’ PET Centre, School of Biomedical Engineering and Imaging Sciences, King's Health Partners, Kings College London, London, United Kingdom – sequence: 9 givenname: NG surname: Mikhaeel fullname: Mikhaeel, NG organization: Department of Clinical Oncology, Guy's Cancer Centre and King's College London University, London, United Kingdom – sequence: 10 givenname: L surname: Ceriani fullname: Ceriani, L organization: Department of Nuclear Medicine and PET/CT Centre, IIMSI - Imaging Institute of Southern Switzerland, Bellinzona, Switzerland – sequence: 11 givenname: E surname: Zucca fullname: Zucca, E organization: SAKK - Swiss Group for Clinical Cancer Research, Bern, Switzerland – sequence: 12 givenname: R surname: Carr fullname: Carr, R organization: Department of Haematology, Guy's and St Thomas’ NHS Foundation Trust and Cancer Division, Kings College London, London, United Kingdom – sequence: 13 givenname: T surname: Györke fullname: Györke, T organization: Department of Nuclear Medicine, Semmelweis University, Budapest, Hungary – sequence: 14 givenname: CN surname: Burggraaff fullname: Burggraaff, CN organization: Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands – sequence: 15 givenname: HCW surname: de Vet fullname: de Vet, HCW organization: Department of Epidemiology and Data Science, Amsterdam UMC, VU University, Amsterdam, The Netherlands – sequence: 16 givenname: OS surname: Hoekstra fullname: Hoekstra, OS organization: Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands – sequence: 17 givenname: JM surname: Zijlstra fullname: Zijlstra, JM organization: Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands – sequence: 18 givenname: VMH surname: Coupé fullname: Coupé, VMH organization: Department of Epidemiology and Data Science, Amsterdam UMC, VU University, Amsterdam, The Netherlands |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34953740$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kE1vGyEQhlGVqPlo_0APFcdedgss7IfUS-M4aSRLiVRXPSIMQ4y1Cy6wkXLqXy-W0xxzmjk876uZ5wKd-OABoU-U1JTQ9uuu1uM01owwWlNaE9K_Q-eMClaxth1OXndBztBFSjtCOkLo8B6dNXwQTcfJOfq7CClXS2tBZ_cEHlLCweKf2xAzeOcf8TqCyhP4jK_nqLILHl-pBAaX5c5niG7CD8s1vp-zDhNg5_FDwUog4d8ub_G1s3ZOgFcqPgK-qjSMI149T_ttmNQHdGrVmODjy7xEv26W68WPanV_e7f4vqo0JyRXZuDMtr0itmsscGoUEBiE6EHwTa83nAGzXPS05dYyZYwAbfjAG7EZdGNUc4m-HHv3MfyZIWU5uXS4RHkIc5KspbwTfdcPBWVHVMeQUgQr9-VHFZ8lJfIgXu7kQbw8iJeUyiK-hD6_9M-bCcxr5L_pAnw7AlC-fHIQZdJFkgbjYnEvTXBv9f8DIx-XeA |
CitedBy_id | crossref_primary_10_1007_s00259_024_06771_1 |
Cites_doi | 10.1200/JCO.2017.76.8093 10.1016/S0140-6736(16)32407-2 10.1182/blood-2013-11-531327 10.1111/bjh.16875 10.1016/j.jval.2016.01.003 10.1016/j.clinthera.2017.05.342 10.1007/s00259-016-3315-7 10.3324/haematol.2016.142752 10.1016/S0140-6736(19)33008-9 10.2967/jnumed.114.145326 10.1182/bloodadvances.2021004467 10.1016/S1470-2045(08)70002-0 10.1016/S1470-2045(11)70235-2 10.1093/annonc/mdv304 10.1007/s00277-012-1530-2 10.1200/JCO.2017.73.3402 10.1056/NEJM199504203321601 10.1177/0272989X12458348 10.1007/s00259-018-4103-3 10.1200/JCO.2014.58.9846 10.1200/JCO.2016.69.0198 10.1200/JCO.2013.53.5229 10.1111/j.1600-0609.2005.00438.x 10.1200/JCO.19.03418 10.2967/jnumed.120.244145 |
ContentType | Journal Article |
Copyright | 2021 Copyright © 2021. Published by Elsevier Inc. |
Copyright_xml | – notice: 2021 – notice: Copyright © 2021. Published by Elsevier Inc. |
CorporateAuthor | PETRA consortium |
CorporateAuthor_xml | – name: PETRA consortium |
DBID | 6I. AAFTH CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
DOI | 10.1016/j.clml.2021.11.008 |
DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2152-2669 |
EndPage | 392 |
ExternalDocumentID | 10_1016_j_clml_2021_11_008 34953740 S2152265021024423 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- --K --M .1- .FO .~1 0R~ 1P~ 1~. 4.4 457 4G. 53G 5VS 6I. 6PF 7-5 8P~ AACTN AAEDT AAEDW AAFTH AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAQQT AAWTL AAXUO ABBQC ABLVK ABMAC ABMZM ABXDB ABYKQ ACDAQ ACGFS ACRLP ADBBV ADEZE ADMUD AEBSH AEKER AENEX AEVXI AFCTW AFKWA AFRHN AFTJW AFXIZ AGHFR AGUBO AGYEJ AIEXJ AIKHN AITUG AJBFU AJOXV AJRQY AJUYK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX AXJTR BKOJK BLXMC BNPGV C45 CAG COF DU5 EBS EFJIC EFLBG EJD EMB EMOBN F5P FDB FEDTE FIRID FNPLU FYGXN GBLVA HVGLF HZ~ KOM LCYCR M41 MET MO0 O-L O9- OAUVE OC~ OO- OVD P-8 P-9 PC. Q38 ROL SDF SEL SES SPCBC SSH SSZ SV3 T5K TEORI XH2 Z5R ~G- AAXKI AFJKZ AKRWK CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-c400t-d942f68a0f73fe41dae0e9558e54b8cb42e2f458164ff2add5ecd49435b9c3da3 |
IEDL.DBID | AIKHN |
ISSN | 2152-2650 |
IngestDate | Fri Aug 16 22:37:38 EDT 2024 Thu Sep 26 16:48:20 EDT 2024 Wed Oct 23 10:01:09 EDT 2024 Fri Feb 23 02:40:30 EST 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 6 |
Keywords | FDG-PET Interim response assessment Health technology assessment Treatment duration Non–Hodgkin lymphoma |
Language | English |
License | This is an open access article under the CC BY-NC-ND license. Copyright © 2021. Published by Elsevier Inc. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c400t-d942f68a0f73fe41dae0e9558e54b8cb42e2f458164ff2add5ecd49435b9c3da3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0002-6151-3382 |
OpenAccessLink | https://www.sciencedirect.com/science/article/pii/S2152265021024423 |
PMID | 34953740 |
PQID | 2614758789 |
PQPubID | 23479 |
PageCount | 11 |
ParticipantIDs | proquest_miscellaneous_2614758789 crossref_primary_10_1016_j_clml_2021_11_008 pubmed_primary_34953740 elsevier_sciencedirect_doi_10_1016_j_clml_2021_11_008 |
PublicationCentury | 2000 |
PublicationDate | June 2022 2022-06-00 20220601 |
PublicationDateYYYYMMDD | 2022-06-01 |
PublicationDate_xml | – month: 06 year: 2022 text: June 2022 |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Clinical lymphoma, myeloma and leukemia |
PublicationTitleAlternate | Clin Lymphoma Myeloma Leuk |
PublicationYear | 2022 |
Publisher | Elsevier Inc |
Publisher_xml | – name: Elsevier Inc |
References | Onkopedia. Diffuses großzelliges B-Zell-Lymphom. Accessed from Dührsen, Müller, Hertenstein (bib0009) 2018; 36 Zorginstituut Nederland. Medicijnkosten. Accessed from Polder, Barendregt, van Oers (bib0020) 2006; 63 Lymfoom. Accessed from Mamot, Klingbiel, Hitz (bib0014) 2015; 33 IKNL. Accessed from Accessed at: January 22, 2021. Zorginstituut Nederland. Richtlijn voor het uitvoeren van economische evaluaties in de gezondheidszorg. 2016 Pfreundschuh, Kuhnt, Trümper (bib0006) 2011; 12 Vitolo, Trněný, Belada (bib0003) 2017; 35 Rekowski, Hüttmann, Schmitz (bib0025) 2021; 62 Accessed at: January 15, 2021. Accessed at: September 4, 2019. Hovon. Accessed from Poeschel, Held, Ziepert (bib0007) 2019; 394 Accessed at: April 25, 2020. Accessed at: February 1, 2021. Mikhaeel, Cunningham, Counsell (bib0013) 2020; 192 M Versteegh, M Vermeulen, M A A Evers (bib0017) 2016; 19 Mihajlović, Bax, van Breugel (bib0034) 2017; 39 Accessed at: May 20, 2020. Burggraaff, de Jong, Hoekstra (bib0008) 2019; 46 Accessed at: 6 March 2021. Doorduijn, Buijt, Holt (bib0018) 2005; 75 Lugtenburg, de Nully Brown, van der Holt (bib0022) 2020 Carr, Fanti, Paez (bib0012) 2014; 55 Zorginstituut Nederland. Kostenhandleiding: Methodologie van kostenonderzoek en referentieprijzen voor economische evaluaties in de gezondheidszorg. 2015 Verdonck, van Putten, Hagenbeek (bib0028) 1995; 332 (bib0033) 2019 Central Bureau for Statistics. Accessed from Blommestein, Verelst, Huijgens (bib0035) 2012; 91 Eertink, Burggraaff, Heymans (bib0024) 2021; 5 van Imhoff, McMillan, Matasar (bib0037) 2017; 35 Briggs, Weinstein, Fenwick (bib0026) 2012; 32 Tilly, Gomes da Silva, Vitolo (bib0015) 2015; 26 Barrington, Mikhaeel, Kostakoglu (bib0016) 2014; 32 Accessed at: January 5, 2021. Pfreundschuh, Schubert, Ziepert (bib0005) 2008; 9 Flinn, der, Kahl (bib0027) 2014; 123 Mikhaeel, Smith, Dunn (bib0011) 2016; 43 Zijlstra, Burggraaff, Kersten, Barrington (bib0004) 2016; 101 Armitage, Gascoyne, Lunning, Cavalli (bib0001) 2017; 390 Nederlandse Zorgautoriteit. Accessed from PETRA consortium. 2019. Accessed from Carr (10.1016/j.clml.2021.11.008_bib0012) 2014; 55 10.1016/j.clml.2021.11.008_bib0029 Mikhaeel (10.1016/j.clml.2021.11.008_bib0013) 2020; 192 Briggs (10.1016/j.clml.2021.11.008_bib0026) 2012; 32 10.1016/j.clml.2021.11.008_bib0021 Mikhaeel (10.1016/j.clml.2021.11.008_bib0011) 2016; 43 10.1016/j.clml.2021.11.008_bib0023 10.1016/j.clml.2021.11.008_bib0002 Barrington (10.1016/j.clml.2021.11.008_bib0016) 2014; 32 Flinn (10.1016/j.clml.2021.11.008_bib0027) 2014; 123 Pfreundschuh (10.1016/j.clml.2021.11.008_bib0005) 2008; 9 Mamot (10.1016/j.clml.2021.11.008_bib0014) 2015; 33 Eertink (10.1016/j.clml.2021.11.008_bib0024) 2021; 5 van Imhoff (10.1016/j.clml.2021.11.008_bib0037) 2017; 35 Vitolo (10.1016/j.clml.2021.11.008_bib0003) 2017; 35 Blommestein (10.1016/j.clml.2021.11.008_bib0035) 2012; 91 Polder (10.1016/j.clml.2021.11.008_bib0020) 2006; 63 10.1016/j.clml.2021.11.008_bib0019 Tilly (10.1016/j.clml.2021.11.008_bib0015) 2015; 26 Doorduijn (10.1016/j.clml.2021.11.008_bib0018) 2005; 75 Armitage (10.1016/j.clml.2021.11.008_bib0001) 2017; 390 Pfreundschuh (10.1016/j.clml.2021.11.008_bib0006) 2011; 12 10.1016/j.clml.2021.11.008_bib0010 10.1016/j.clml.2021.11.008_bib0032 (10.1016/j.clml.2021.11.008_bib0033) 2019 10.1016/j.clml.2021.11.008_bib0036 M Versteegh (10.1016/j.clml.2021.11.008_bib0017) 2016; 19 Lugtenburg (10.1016/j.clml.2021.11.008_bib0022) 2020 Dührsen (10.1016/j.clml.2021.11.008_bib0009) 2018; 36 Mihajlović (10.1016/j.clml.2021.11.008_bib0034) 2017; 39 Verdonck (10.1016/j.clml.2021.11.008_bib0028) 1995; 332 10.1016/j.clml.2021.11.008_bib0030 Burggraaff (10.1016/j.clml.2021.11.008_bib0008) 2019; 46 10.1016/j.clml.2021.11.008_bib0031 Zijlstra (10.1016/j.clml.2021.11.008_bib0004) 2016; 101 Poeschel (10.1016/j.clml.2021.11.008_bib0007) 2019; 394 Rekowski (10.1016/j.clml.2021.11.008_bib0025) 2021; 62 |
References_xml | – volume: 43 start-page: 1209 year: 2016 end-page: 1219 ident: bib0011 article-title: Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL publication-title: Eur. J. Nucl. Med. Mol. Imaging contributor: fullname: Dunn – volume: 36 start-page: 2024 year: 2018 end-page: 2034 ident: bib0009 article-title: Positron emission tomography-guided therapy of aggressive non-hodgkin lymphomas (PETAL): a multicenter, randomized phase III trial publication-title: J. Clin. Oncol. contributor: fullname: Hertenstein – year: 2020 ident: bib0022 article-title: Rituximab-CHOP with early rituximab intensification for diffuse large B-Cell lymphoma: a randomized phase III trial of the HOVON and the Nordic lymphoma group (HOVON-84) publication-title: J. Clin. Oncol. contributor: fullname: van der Holt – volume: 9 start-page: 105 year: 2008 end-page: 116 ident: bib0005 article-title: Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60) publication-title: Lancet Oncol contributor: fullname: Ziepert – volume: 394 start-page: 2271 year: 2019 end-page: 2281 ident: bib0007 article-title: Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial publication-title: Lancet contributor: fullname: Ziepert – volume: 192 start-page: 504 year: 2020 end-page: 513 ident: bib0013 article-title: FDG-PET/CT after two cycles of R-CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome - final result of a UK national cancer research Institute prospective study publication-title: Br. J. Haematol. contributor: fullname: Counsell – volume: 26 start-page: v116 year: 2015 end-page: v125 ident: bib0015 article-title: Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up publication-title: Ann. Oncol. contributor: fullname: Vitolo – volume: 32 start-page: 722 year: 2012 end-page: 732 ident: bib0026 article-title: Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM modeling good research practices task force working group-6 publication-title: Med. Decis. Mak. contributor: fullname: Fenwick – volume: 123 start-page: 2944 year: 2014 end-page: 2952 ident: bib0027 article-title: Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study publication-title: Blood contributor: fullname: Kahl – volume: 46 start-page: 65 year: 2019 end-page: 79 ident: bib0008 article-title: Predictive value of interim positron emission tomography in diffuse large B-cell lymphoma: a systematic review and meta-analysis publication-title: Eur. J. Nucl. Med. Mol. Imaging. contributor: fullname: Hoekstra – volume: 62 start-page: 37 year: 2021 end-page: 42 ident: bib0025 article-title: Interim PET evaluation in diffuse large B-cell lymphoma using published recommendations: comparison of the deauville 5-point scale and the ΔSUVmax method publication-title: J. Nucl. Med. contributor: fullname: Schmitz – volume: 35 start-page: 3529 year: 2017 end-page: 3537 ident: bib0003 article-title: Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-Cell lymphoma publication-title: J. Clin. Oncol. contributor: fullname: Belada – volume: 390 start-page: 298 year: 2017 end-page: 310 ident: bib0001 article-title: Non-Hodgkin lymphoma publication-title: The Lancet contributor: fullname: Cavalli – volume: 19 start-page: 343 year: 2016 end-page: 352 ident: bib0017 article-title: Dutch tariff for the five-level version of EQ-5D publication-title: Value Health contributor: fullname: M A A Evers – volume: 5 start-page: 2375 year: 2021 end-page: 2384 ident: bib0024 article-title: Optimal timing and criteria of interim-PET in DLBCL: a comparative study of 1692 patients publication-title: Blood Adv contributor: fullname: Heymans – volume: 12 start-page: 1013 year: 2011 end-page: 1022 ident: bib0006 article-title: CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera international trial (MInT) group publication-title: Lancet Oncol contributor: fullname: Trümper – volume: 91 start-page: 1945 year: 2012 end-page: 1952 ident: bib0035 article-title: Real-world costs of autologous and allogeneic stem cell transplantations for haematological diseases: a multicentre study publication-title: Ann. Hematol. contributor: fullname: Huijgens – volume: 332 start-page: 1045 year: 1995 end-page: 1051 ident: bib0028 article-title: Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma publication-title: N. Engl. J. Med. contributor: fullname: Hagenbeek – volume: 55 start-page: 1936 year: 2014 end-page: 1944 ident: bib0012 article-title: Prospective international cohort study demonstrates inability of interim PET to predict treatment failure in diffuse large B-cell lymphoma publication-title: J. Nucl. Med. contributor: fullname: Paez – volume: 63 start-page: 1720 year: 2006 end-page: 1731 ident: bib0020 article-title: Health care costs in the last year of life–the Dutch experience publication-title: Soc. Sci. Med. 1982 contributor: fullname: van Oers – volume: 75 start-page: 116 year: 2005 end-page: 123 ident: bib0018 article-title: Self-reported quality of life in elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy publication-title: Eur. J. Haematol. contributor: fullname: Holt – volume: 32 start-page: 3048 year: 2014 end-page: 3058 ident: bib0016 article-title: Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphomas imaging working group publication-title: J. Clin. Oncol. contributor: fullname: Kostakoglu – year: 2019 ident: bib0033 article-title: Standaardschema’s chemotherapie voor patiënten buiten protocol publication-title: Vadem. Hematol. – volume: 39 start-page: 1221 year: 2017 end-page: 1232.e4 ident: bib0034 article-title: Microcosting study of Rituximab subcutaneous injection versus intravenous infusion publication-title: Clin. Ther. contributor: fullname: van Breugel – volume: 101 start-page: 1279 year: 2016 end-page: 1283 ident: bib0004 article-title: FDG-PET as a biomarker for early response in diffuse large B-cell lymphoma as well as in Hodgkin lymphoma? Ready for implementation in clinical practice? publication-title: Haematologica contributor: fullname: Barrington – volume: 33 start-page: 2523 year: 2015 end-page: 2529 ident: bib0014 article-title: Final results of a prospective evaluation of the predictive value of interim positron emission tomography in patients with diffuse large B-Cell lymphoma treated with R-CHOP-14 (SAKK 38/07) publication-title: J. Clin. Oncol. contributor: fullname: Hitz – volume: 35 start-page: 544 year: 2017 end-page: 551 ident: bib0037 article-title: Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: the ORCHARRD study publication-title: J. Clin. Oncol. contributor: fullname: Matasar – volume: 36 start-page: 2024 year: 2018 ident: 10.1016/j.clml.2021.11.008_bib0009 article-title: Positron emission tomography-guided therapy of aggressive non-hodgkin lymphomas (PETAL): a multicenter, randomized phase III trial publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2017.76.8093 contributor: fullname: Dührsen – volume: 390 start-page: 298 year: 2017 ident: 10.1016/j.clml.2021.11.008_bib0001 article-title: Non-Hodgkin lymphoma publication-title: The Lancet doi: 10.1016/S0140-6736(16)32407-2 contributor: fullname: Armitage – volume: 123 start-page: 2944 year: 2014 ident: 10.1016/j.clml.2021.11.008_bib0027 article-title: Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study publication-title: Blood doi: 10.1182/blood-2013-11-531327 contributor: fullname: Flinn – year: 2019 ident: 10.1016/j.clml.2021.11.008_bib0033 article-title: Standaardschema’s chemotherapie voor patiënten buiten protocol publication-title: Vadem. Hematol. – volume: 192 start-page: 504 issue: 3 year: 2020 ident: 10.1016/j.clml.2021.11.008_bib0013 article-title: FDG-PET/CT after two cycles of R-CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome - final result of a UK national cancer research Institute prospective study publication-title: Br. J. Haematol. doi: 10.1111/bjh.16875 contributor: fullname: Mikhaeel – ident: 10.1016/j.clml.2021.11.008_bib0010 – volume: 19 start-page: 343 year: 2016 ident: 10.1016/j.clml.2021.11.008_bib0017 article-title: Dutch tariff for the five-level version of EQ-5D publication-title: Value Health doi: 10.1016/j.jval.2016.01.003 contributor: fullname: M Versteegh – ident: 10.1016/j.clml.2021.11.008_bib0029 – volume: 39 start-page: 1221 year: 2017 ident: 10.1016/j.clml.2021.11.008_bib0034 article-title: Microcosting study of Rituximab subcutaneous injection versus intravenous infusion publication-title: Clin. Ther. doi: 10.1016/j.clinthera.2017.05.342 contributor: fullname: Mihajlović – volume: 43 start-page: 1209 year: 2016 ident: 10.1016/j.clml.2021.11.008_bib0011 article-title: Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL publication-title: Eur. J. Nucl. Med. Mol. Imaging doi: 10.1007/s00259-016-3315-7 contributor: fullname: Mikhaeel – ident: 10.1016/j.clml.2021.11.008_bib0031 – volume: 101 start-page: 1279 year: 2016 ident: 10.1016/j.clml.2021.11.008_bib0004 article-title: FDG-PET as a biomarker for early response in diffuse large B-cell lymphoma as well as in Hodgkin lymphoma? Ready for implementation in clinical practice? publication-title: Haematologica doi: 10.3324/haematol.2016.142752 contributor: fullname: Zijlstra – volume: 394 start-page: 2271 year: 2019 ident: 10.1016/j.clml.2021.11.008_bib0007 article-title: Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial publication-title: Lancet doi: 10.1016/S0140-6736(19)33008-9 contributor: fullname: Poeschel – volume: 55 start-page: 1936 year: 2014 ident: 10.1016/j.clml.2021.11.008_bib0012 article-title: Prospective international cohort study demonstrates inability of interim PET to predict treatment failure in diffuse large B-cell lymphoma publication-title: J. Nucl. Med. doi: 10.2967/jnumed.114.145326 contributor: fullname: Carr – ident: 10.1016/j.clml.2021.11.008_bib0023 – volume: 5 start-page: 2375 year: 2021 ident: 10.1016/j.clml.2021.11.008_bib0024 article-title: Optimal timing and criteria of interim-PET in DLBCL: a comparative study of 1692 patients publication-title: Blood Adv doi: 10.1182/bloodadvances.2021004467 contributor: fullname: Eertink – volume: 9 start-page: 105 year: 2008 ident: 10.1016/j.clml.2021.11.008_bib0005 article-title: Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60) publication-title: Lancet Oncol doi: 10.1016/S1470-2045(08)70002-0 contributor: fullname: Pfreundschuh – volume: 12 start-page: 1013 year: 2011 ident: 10.1016/j.clml.2021.11.008_bib0006 article-title: CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera international trial (MInT) group publication-title: Lancet Oncol doi: 10.1016/S1470-2045(11)70235-2 contributor: fullname: Pfreundschuh – ident: 10.1016/j.clml.2021.11.008_bib0021 – volume: 26 start-page: v116 issue: 5 year: 2015 ident: 10.1016/j.clml.2021.11.008_bib0015 article-title: Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up publication-title: Ann. Oncol. doi: 10.1093/annonc/mdv304 contributor: fullname: Tilly – ident: 10.1016/j.clml.2021.11.008_bib0002 – volume: 91 start-page: 1945 year: 2012 ident: 10.1016/j.clml.2021.11.008_bib0035 article-title: Real-world costs of autologous and allogeneic stem cell transplantations for haematological diseases: a multicentre study publication-title: Ann. Hematol. doi: 10.1007/s00277-012-1530-2 contributor: fullname: Blommestein – ident: 10.1016/j.clml.2021.11.008_bib0019 – volume: 35 start-page: 3529 year: 2017 ident: 10.1016/j.clml.2021.11.008_bib0003 article-title: Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-Cell lymphoma publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2017.73.3402 contributor: fullname: Vitolo – volume: 332 start-page: 1045 year: 1995 ident: 10.1016/j.clml.2021.11.008_bib0028 article-title: Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma publication-title: N. Engl. J. Med. doi: 10.1056/NEJM199504203321601 contributor: fullname: Verdonck – volume: 32 start-page: 722 year: 2012 ident: 10.1016/j.clml.2021.11.008_bib0026 article-title: Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM modeling good research practices task force working group-6 publication-title: Med. Decis. Mak. doi: 10.1177/0272989X12458348 contributor: fullname: Briggs – ident: 10.1016/j.clml.2021.11.008_bib0036 – volume: 46 start-page: 65 year: 2019 ident: 10.1016/j.clml.2021.11.008_bib0008 article-title: Predictive value of interim positron emission tomography in diffuse large B-cell lymphoma: a systematic review and meta-analysis publication-title: Eur. J. Nucl. Med. Mol. Imaging. doi: 10.1007/s00259-018-4103-3 contributor: fullname: Burggraaff – volume: 33 start-page: 2523 year: 2015 ident: 10.1016/j.clml.2021.11.008_bib0014 article-title: Final results of a prospective evaluation of the predictive value of interim positron emission tomography in patients with diffuse large B-Cell lymphoma treated with R-CHOP-14 (SAKK 38/07) publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2014.58.9846 contributor: fullname: Mamot – volume: 35 start-page: 544 year: 2017 ident: 10.1016/j.clml.2021.11.008_bib0037 article-title: Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: the ORCHARRD study publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2016.69.0198 contributor: fullname: van Imhoff – volume: 63 start-page: 1720 year: 2006 ident: 10.1016/j.clml.2021.11.008_bib0020 article-title: Health care costs in the last year of life–the Dutch experience publication-title: Soc. Sci. Med. 1982 contributor: fullname: Polder – volume: 32 start-page: 3048 year: 2014 ident: 10.1016/j.clml.2021.11.008_bib0016 article-title: Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphomas imaging working group publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2013.53.5229 contributor: fullname: Barrington – ident: 10.1016/j.clml.2021.11.008_bib0030 – volume: 75 start-page: 116 year: 2005 ident: 10.1016/j.clml.2021.11.008_bib0018 article-title: Self-reported quality of life in elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy publication-title: Eur. J. Haematol. doi: 10.1111/j.1600-0609.2005.00438.x contributor: fullname: Doorduijn – ident: 10.1016/j.clml.2021.11.008_bib0032 – year: 2020 ident: 10.1016/j.clml.2021.11.008_bib0022 article-title: Rituximab-CHOP with early rituximab intensification for diffuse large B-Cell lymphoma: a randomized phase III trial of the HOVON and the Nordic lymphoma group (HOVON-84) publication-title: J. Clin. Oncol. doi: 10.1200/JCO.19.03418 contributor: fullname: Lugtenburg – volume: 62 start-page: 37 year: 2021 ident: 10.1016/j.clml.2021.11.008_bib0025 article-title: Interim PET evaluation in diffuse large B-cell lymphoma using published recommendations: comparison of the deauville 5-point scale and the ΔSUVmax method publication-title: J. Nucl. Med. doi: 10.2967/jnumed.120.244145 contributor: fullname: Rekowski |
SSID | ssj0070019 |
Score | 2.3372695 |
Snippet | Guideline recommendations for diffuse large-B-cell lymphoma (DLBCL) treatment are shifting from long to short treatment duration, although it is still unclear... BACKGROUNDGuideline recommendations for diffuse large-B-cell lymphoma (DLBCL) treatment are shifting from long to short treatment duration, although it is... |
SourceID | proquest crossref pubmed elsevier |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 382 |
SubjectTerms | Cost-Benefit Analysis Duration of Therapy FDG-PET Health technology assessment Humans Interim response assessment Lymphoma, Large B-Cell, Diffuse - diagnostic imaging Lymphoma, Large B-Cell, Diffuse - drug therapy Lymphoma, Large B-Cell, Diffuse - economics Non–Hodgkin lymphoma Positron-Emission Tomography Treatment duration |
Title | Cost-Effectiveness of Shortening Treatment Duration Based on Interim PET Outcome in Patients With Diffuse Large B-cell Lymphoma |
URI | https://dx.doi.org/10.1016/j.clml.2021.11.008 https://www.ncbi.nlm.nih.gov/pubmed/34953740 https://search.proquest.com/docview/2614758789 |
Volume | 22 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwEB7BIlW9VPS9tEWu1FtlNg87jyMsoG0LFIlF5WY5fohU3QSxyaEX-OvM5FGpUttDb1EUK9F8k5lvHh4DfAgTkwZ5KrlMMs9FpC0vrA-4EUanqEXWdhXT07NkcSk-X8mrDZiPe2GorXKw_b1N76z1cGc2SHN2U5azCzqRNUKCQUGLQFawCVvojoSYwNb-py-Ls9EgU2WVWDA9z2nBsHemb_MyP1ZUgYjCPRrmSadM_tk__Y1_dn7oeBueDASS7fff-BQ2XPUMHp0OJfLncD-v1w3vhxIPlozVnl1cU1ctJUHYcuwtZ4dtjz87QF9mGV50CcJyxc6Pluxr26BUHCsrdt5PX12zb2VzzQ5L79u1YyfURc4OOCX_2clP1It6pV_A5fHRcr7gwykLiEcQNNzmIvJJpgOfxt6J0GoXuFzKzElRZKYQkYu8kBnGVd4jllY6Y0WONKvITWx1_BImVV2518A0WgeDLt_rOBYuklmeFEivwkxbE5g4mcLHUbbqph-mocYus--KkFCEBEYlCpGYghzFr35TCYXW_p_r3o9YKfxXSAa6cnW7VhgtCoyP0iyfwqsexF_fEVOjbSqCnf986xt4HNHOiC5B8xYmzW3r3iFfaYpd2Ny7C3cHrXwA_O7pQA |
link.rule.ids | 315,786,790,4521,24144,27955,27956,45618,45712 |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9RADLbaIlEuiEdbllcHiVs13Wwyk8eRblstZbdU6lbtbTSZhxrEJhWbHLjAX8fOoxIScOAWRYkysh37s_2NB-D9JDZJkCWSyzj1XITa8tz6gBthdIJWZG3bMV2cx7MrcXYjbzZgOuyFIVpl7_s7n9566_7OuJfm-K4oxpd0ImuIAIOSFoGoYBMeEBogXtfhj3ueB_VVCQPT05we73fOdCQv83VF_YdwckijPOmMyT9Hp7-hzzYKnT6Bxz18ZB-6FT6FDVc-g4eLvkH-HH5Oq3XNu5HEvR9jlWeXt8SppRIIWw7McnbcdNpnRxjJLMOLtjxYrNjFyZJ9bmqUiWNFyS662atrdl3Ut-y48L5ZOzYnDjk74lT6Z_PvaBXVSu_A1enJcjrj_RkLqI0gqLnNROjjVAc-ibwTE6td4DIpUydFnppchC70QqaYVXmPmrTSGSsyBFl5ZiKro13YKqvSvQCm0TcYDPheR5FwoUyzOEdwNUm1NYGJ4hEcDLJVd90oDTVwzL4o0oQiTWBOolATI5CD-NVvBqHQ1__zvXeDrhT-KSQDXbqqWSvMFQVmR0majWCvU-L9OiKi2SYiePmfX92H7dlyMVfzj-efXsGjkPZItKWa17BVf2vcG0Qudf62tcxfDfHqFQ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cost-Effectiveness+of+Shortening+Treatment+Duration+Based+on+Interim+PET+Outcome+in+Patients+With+Diffuse+Large+B-cell+Lymphoma&rft.jtitle=Clinical+lymphoma%2C+myeloma+and+leukemia&rft.au=Greuter%2C+Mje&rft.au=Eertink%2C+J+J&rft.au=Jongeneel%2C+G&rft.au=D%C3%BChrsen%2C+U&rft.date=2022-06-01&rft.eissn=2152-2669&rft.volume=22&rft.issue=6&rft.spage=382&rft_id=info:doi/10.1016%2Fj.clml.2021.11.008&rft_id=info%3Apmid%2F34953740&rft.externalDocID=34953740 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2152-2650&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2152-2650&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2152-2650&client=summon |